Study Group: Clozaril Prescribers (US)(?)
Council Members in this Study Group: 42
Request a survey with this Study Group
Leading Experts in this Study Group
 |
What is a GLG Leader? |
Founder and Director
Institute for Integrative Psychiatry
Rami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Physicians who Treat Schizophrenia (US) | 311 |
| Psychiatrists (US) | 1099 |
| Psychiatrists | 1428 |
| Physicians who Treat ADHD (US) | 370 |
| Seroquel Prescribers forSchizophrenia (US) | 101 |
| Effexor XR Prescribers (US) | 137 |
| Physicians who Treat Depression (US) | 357 |
GLG NewsSMAnalyses by this Study Group's Experts(?)
Direct comparisons between potential competing agents often do not exist Initial FDA approval is usually based on comparisons to placebo A new approval does necessarily mean that the new agent is better than existing ones, although this is implied by industry Industry bears all the costs of efficacy...
All currently marketed antipsychotic medications for treating schizophrenia rely on mechanisms of action which target dopamine and serotonin receptors. Although these medications reduce delusions and hallucinations without inducing symptoms of Parkinson's Disease...
The clinical trial which was done has shown only comparable efficacy to available treatment for positive symptoms. It did not study efficacy for cognition or negative symptoms. It did not test efficacy in treatment resistant patients. It did not show long term efficacy. It did not show that...
Pfizer Inc (NYSE:PFE) and Taisho Pharmaceutical Co., Ltd. (OTC:TSOPF.PK) announced the signing of a definitive agreement for worldwide collaboration to research, develop and commercialize TS-032. TS-032 is a metabotropic glutamate receptor (mGluR) agonist, a novel drug candidate for the...
Addex Pharmaceuticals (Swiss:ADXN.SW) announced on January 3, 2008 an exclusive worldwide license agreement with Merck & Co., Inc. (NYSE:MRK) to develop ADX63365, a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5) with potential for the...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Government/Military Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Facility, Academic Medical Center
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- Medical Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms